Loading...
Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial
OBJECTIVES: Cetuximab plus leucovorin, fluorouracil and oxaliplatin (FOLFOX-4) is superior to FOLFOX-4 alone as a first-line treatment for patients with metastatic colorectal cancer with RAS wild-type (RAS wt mCRC), with significantly improved survival benefit by TAILOR, an open-label, randomised, m...
Na minha lista:
| Udgivet i: | BMJ Open |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMJ Publishing Group
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7044820/ https://ncbi.nlm.nih.gov/pubmed/32051297 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2019-030738 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|